{
    "clinical_study": {
        "@rank": "13121", 
        "acronym": "TaMoVac II", 
        "arm_group": [
            {
                "arm_group_label": "2 injections of DNA administered by Zetajet", 
                "arm_group_type": "Experimental", 
                "description": "This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml"
            }, 
            {
                "arm_group_label": "2 injections DNA  by Zetajet and electroporation", 
                "arm_group_type": "Experimental", 
                "description": "This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml followed by electroporation using the Derma Vax device."
            }, 
            {
                "arm_group_label": "1 injection DNA by Zetajet and electroporation", 
                "arm_group_type": "Experimental", 
                "description": "This arm will receive 600 micrograms of HIVIS DNA given in 1 injection using the Zetajet device the injection will comprise of 0.1 ml at a concentration of 6mg/ml followed by electroporation using the Derma Vax device."
            }
        ], 
        "brief_summary": {
            "textblock": "Electroporation will increase the efficiency of DNA priming in terms of immune responses and\n      will lead to a dose sparing DNA vaccine regimen. Furthermore increased DNA vaccine\n      concentration will reduce the number of shots necessary to deliver the full dose and induce\n      comparable immune responses as with lower DNA vaccine concentrations."
        }, 
        "brief_title": "A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet\u00ae With or Without ID Derma Vax\u2122 Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Vaccines", 
            "HIV", 
            "Safety", 
            "Immunogenicity"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing to undergo counselling and HIV testing.\n\n          -  Have a negative antigen/antibody ELISA for HIV infection.\n\n          -  Able to give informed consent.\n\n          -  Basic abilities to read and write.\n\n          -  Satisfactory completion of an assessment of understanding prior to enrolment defined\n             as 90% correct answers after three opportunities to take test.\n\n          -  Resident of the region where the study is taking place.\n\n          -  At low risk of HIV infection.\n\n          -  Verbal assurances for adequate birth control measures.\n\n          -  Healthy as evidenced by clinical and laboratory measures\n\n        Exclusion Criteria:\n\n          -  At risk of HIV infection.\n\n          -  Active tuberculosis.\n\n          -  A history of immunodeficiency, ongoing medical and/or psychiatric condition and/or\n             chronic illness requiring continuous or frequent medical intervention.\n\n          -  Autoimmune disease.\n\n          -  Hives and severe eczema.\n\n          -  Substance abuse problems.\n\n          -  History of grand-mal epilepsy.\n\n          -  Received blood or blood products or immunoglobulins in the past 3 months.\n\n          -  Receiving immunosuppressive therapy such as systemic corticosteroids or cancer\n             chemotherapy.\n\n          -  Use of experimental therapeutic agents within 30 days of study entry.\n\n          -  History of cardiac disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "198", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697007", 
            "org_study_id": "TaMoVac II"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "2 injections of DNA administered by Zetajet", 
                    "2 injections DNA  by Zetajet and electroporation", 
                    "1 injection DNA by Zetajet and electroporation"
                ], 
                "intervention_name": "HIVIS DNA vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "2 injections of DNA administered by Zetajet", 
                    "2 injections DNA  by Zetajet and electroporation", 
                    "1 injection DNA by Zetajet and electroporation"
                ], 
                "intervention_name": "Zetajet", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "2 injections DNA  by Zetajet and electroporation", 
                    "1 injection DNA by Zetajet and electroporation"
                ], 
                "intervention_name": "Derma Vax Electroporation", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "2 injections of DNA administered by Zetajet", 
                    "2 injections DNA  by Zetajet and electroporation", 
                    "1 injection DNA by Zetajet and electroporation"
                ], 
                "intervention_name": "Modified Vaccinia Ankara (MVA-CDMR)", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Maputo", 
                        "country": "Mozambique"
                    }, 
                    "name": "Instituto Nacional de Saude"
                }, 
                "investigator": [
                    {
                        "last_name": "Ilesh Jani, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Edna Viegas, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "drbakari@yahoo.com", 
                    "last_name": "Muhammad Bakari, MD,MMed, PhD", 
                    "phone": "+255754387328"
                }, 
                "contact_backup": {
                    "email": "patricia.munseri@ki.se", 
                    "last_name": "Patricia Munseri, MD, MMed", 
                    "phone": "+255754562784"
                }, 
                "facility": {
                    "address": {
                        "city": "Dar es Salaam", 
                        "country": "Tanzania"
                    }, 
                    "name": "Muhimbili University of Health and Allied Sciences"
                }, 
                "investigator": [
                    {
                        "last_name": "Muhammad Bakari, MD, MMED, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Patricia Munseri, MD, MMED", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mbeya", 
                        "country": "Tanzania"
                    }, 
                    "name": "Mbeya Medical Research Programme"
                }, 
                "investigator": [
                    {
                        "last_name": "Leonard Maboko, MD, MSc", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Philipp Mann, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Mozambique", 
                "Tanzania"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet\u00ae With or Without ID Derma Vax\u2122 Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique", 
        "other_outcome": [
            {
                "measure": "Any grade of adverse event that results in a clinical decision to discontinue further immunizations.", 
                "safety_issue": "Yes", 
                "time_frame": "After receiving the first immunization until 64 weeks from enrollment"
            }, 
            {
                "measure": "The presence of HIV-specific binding antibodies and the titer when these are present", 
                "safety_issue": "No", 
                "time_frame": "Up to week 64 from enrollment"
            }, 
            {
                "measure": "The presence of neutralizing antibodies and the titer when these are present", 
                "safety_issue": "No", 
                "time_frame": "Approximately between week 64-68 after enrollment"
            }, 
            {
                "measure": "The magnitude of interferon gamma ELISpot responses measured by the number of spot forming cells per million PBMCs in response to pools of HIV-peptides in the assay", 
                "safety_issue": "No", 
                "time_frame": "2 weeks post the last vaccination"
            }, 
            {
                "measure": "Any grade of adverse event that occurs in a participant that has received at lease one immunization", 
                "safety_issue": "Yes", 
                "time_frame": "After the first immunization up to 64 weeks"
            }
        ], 
        "overall_contact": {
            "email": "elyamuya@yahoo.com", 
            "last_name": "Eligius Lyamuya, MD, MMED, PHD", 
            "phone": "+255786172528"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Tanzania: Food & Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The presence of an interferon gamma ELISpot responses to a pool of HIV peptides encoded by the vaccine to which there was no response at baseline", 
                "safety_issue": "No", 
                "time_frame": "2 weeks after the last vaccination"
            }, 
            {
                "measure": "Grade 3 or above local and systemic solicited adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Within 2 weeks post each immunization up to week 64 from enrollment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697007"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Muhimbili University of Health and Allied Sciences", 
            "investigator_full_name": "Patricia Jane Munseri", 
            "investigator_title": "Prof Eligius Lyamuya", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The presence of CD4+ and CD8+ T-cell cytokine responses to pools of HIV peptides assessed by Intracellular cytokine staining", 
            "safety_issue": "No", 
            "time_frame": "2 weeks post last vaccination"
        }, 
        "source": "Muhimbili University of Health and Allied Sciences", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Swedish Institute for Infectious Disease Control", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Karolinska Institutet", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "US Military HIV Research Program", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Medical Research Council", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Institute for Medical Research, Tanzania", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ludwig-Maximilians - University of Munich", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Imperial College London", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Mbeya medical research program", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Instituto Nacional de Sa\u00fade, Mozambique", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Muhimbili University of Health and Allied Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}